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Advanced Glycation End Products (AGEs) are toxins that are involved in structural and functional al-
terations of several organs and tissues, resulting in various pathologies. Several types of AGEs have been
described but carboxymethyllysine (CML) is the major antigenic AGE compound. In this study, three
different immunogenic carrier proteins (KLH, keyhole limpet hemocyanin; BSA, bovine serum albumin;
and HSA, human serum albumin) were modiﬁed by glycation. The glycated molecules were used to
produce epitope-speciﬁc monoclonal antibodies able to recognize the CML domain and to detect uremic
toxins in the serum of patients with chronic kidney disease (CKD). A competitive ELISA was standardized
in order to quantify CML in the sera of CKD patients. An increase in uremic toxins can compromise the
clinical condition of these patients, thus, the detection and quantiﬁcation of these toxins should con-
tribute to a better management and understanding of this disease.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic kidney disease (CKD) is a gradual loss of kidney func-
tion over time which is currently considered as one of the most
signiﬁcant medical and health problems. Cases of CKD are growing
exponentially, and, together with other chronic and non-trans-
missible diseases, CKD is responsible for millions of deaths per
year [1,2]. CKD is classically deﬁned by the presence of a renal
parenchymal lesion and/or by a diminution in renal function for a
period equal to or greater than three months, and by proteinuria.
This deﬁnition enables the classiﬁcation of CKD into ﬁve stages:
stage 1 is the less severe, with a glomerular ﬁltration rate (GFR)Z
90 mL/min/1.73 m2, and stage 5 is the most severe, with a GFR
o15 mL/min/1.73 m2 (or dialysis) [3]. As a consequence of GFR
alteration, there is a progressive retention of a great number of
components, which would normally be eliminated by the kidneys
under healthy conditions. The increased presence of these mole-
cules and their pathological effects on the body allow to designate
them as uremic toxins. The accumulation of these uremic toxins inB.V. This is an open access article uthe circulation characterizes uremic syndrome [4].
To date, more than 150 uremic compounds have been de-
scribed. Among these, those classiﬁed as protein-bound com-
pounds require special attention because they are associated with
toxic activities in different biological systems and are difﬁcult to
remove by dialysis. Among these toxins, Advanced Glycation End
Products (AGEs) are some of the main substances involved in
various effects in the body such as vascular lesions and white
blood cell and platelet toxicity [4,5].
AGEs represent a heterogeneous group of substances formed by
amino-carbonyl non-enzymatic interactions between reducing
sugars or oxidized lipids and proteins, amino phospholipids, or
nucleic acids [6]. These complex reactions are initiated with the
formation of an unstable Schiff base, generated by the condensa-
tion of a reducing sugar carbonyl group, such as glucose, with an
amine group, originating from an amino acid that is especially
susceptible to the reaction, such as a lysine residue. During AGE
formation, different structures are formed, including carbox-
yethyllysine (CEL), imidazolone, pentosidine, pirraline, and car-
boxymethyllysine (CML). However, CML is the most abundant
modiﬁcation that occurs by protein glycation [7].
Several studies have shown that CML modiﬁcations occur
during aging, in oxidative stress, and in the pathogenesis ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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retinopathy, hemodialysis-associated amyloidosis, Alzheimer's
disease, dysfunctions in bone remodeling, and arterial stiffening
[5,8,9]. In CKD, the level of AGEs is signiﬁcantly increased, not only
because of increased production of AGEs, but also because of de-
creased excretion [4].
Considering the importance of conditions related to increased
circulating AGEs, detection, quantiﬁcation, and understanding the
cytotoxic effects of AGEs is important. However, these molecules
are not frequently titrated, except for glycated hemoglobin
(HbA1C), which is quantiﬁed in patients with diabetes mellitus
[10]. An analysis of the biochemical and immunological properties
of AGEs can provide important information about these
biomarkers.
Immunological methods may provide several advantages in
identifying these compounds, such as fast achievement of results,
higher sensitivity, and easier application [11]. Currently, no gold
standard method is available for detection and quantiﬁcation of
AGEs. One possible explanation for this is that there is no inter-
nationally recognized standard unit of measurement to express
AGEs levels, unlike other measurable molecules, which makes the
comparison of results between different laboratories extremely
difﬁcult. Thus, the development of a speciﬁc and sensitive tool for
the detection and quantiﬁcation of AGEs is required to be used in
diagnosis in order to understand different processes and also to
help patients with appropriate treatment [12].
In order to detect circulating levels of CML in CKD patients,
various biochemical and immunological approaches have been
employed. The objective of the present study was to produce
speciﬁc antibody probes that can be used to detect and quantify
circulating levels of CML in biological ﬂuids of CKD patients.
Moreover, such target-speciﬁc antibodies may be employed in in
vitro assays as blocker or competitor molecules to promote a
greater understanding of the cytotoxic effects of AGEs.2. Methodology
All the experiments were conducted in accordance with the
guidelines of the Ethical Committee in Health of the UFPR (No
39393414.9.0000.0102, CEP/SD), and the Helsinki Declaration of
1975, promulgated by the World Medical Association. In addition,
this study was approved by the Animal Ethical Committee of UFPR
(No 23,075.087228/2013-74) according to the guidelines of the
Brazilian College of Animal Experimentation (COBEA).
2.1. Patients
For the present study, peripheral blood samples were collected
from 24 patients from our CKD clinic in Nossa Senhora da Luz
Hospital (Curitiba/Brazil). The inclusion criteria were 18 years of
age and older, presence of CKD (proteinuria or decreased GFR in
3 consecutive evaluations), and willingness to participate in the
study. Exclusion criteria were signs of active inﬂammation or in-
fectious disease (determined by the absence of clinical signs of
acute inﬂammation), malignancy, prior or current renal replace-
ment therapy, and the use of immunosuppressive drugs. Clinical
data were obtained by chart review. All clinical laboratory results
recorded from chart review represented values measured in the
clinical laboratory of Sugisawa by standard auto analyzer techni-
ques. GFR was measured according to estimating equations de-
veloped by the Modiﬁcation of Diet in Renal Disease (MDRD).
2.2. Collection of samples for in vivo and in vitro studies
On the morning of enrollment in the study, serum wascollected, divided into aliquots, and stored at 80 °C. Patients
were classiﬁed in stages 1–5 according to the National Kidney
Foundation criteria [3].
2.3. Glycated protein synthesis
In order to generate CML, protein reactions with glyoxylic acid
in the presence of sodium cyanoborohydride were performed as
previously described [13,14]. We synthesized CML-BSA (bovine
serum albumin), CML-KLH (keyhole limpet hemocyanin), and
CML-HSA (human serum albumin) (All reagents were purchased
Sigma-Aldrich, St. Louis, MO). The ﬁnal protein concentration was
determined using the Bradford assay (Bio-Rad, United States).
2.4. Characterization of CML and glycated proteins
The glycated molecules were characterized by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and mass
spectrometry. SDS-PAGE was performed under reducing condi-
tions, in order to assess the protein proﬁle of each CML-protein. In
summary, 10 μg of each sample was electrophoresed in a 10% re-
solving gel at 100 V for 90 min at room temperature. After, the gels
were stained with Coomassie Blue. For mass spectrometry (MS)
proteins were directly spotted on to a MALDI target plate with
alpha-cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Aldrich, St.
Louis, MO) as a matrix (prepared in 50% acetonitrile and 0.1%tri-
ﬂuoroacetic acid). MALDI-TOF analysis was performed using a
mass spectrometer MALDI-Tof/Tof Autoﬂex II (Bruker Daltonics);
MS spectra were acquired and analyzed on Flex Analysis 2.0
(Bruker Daltonics) software.
2.5. Development of murine anti-CML antibodies
BALB/C mice (four mice, male, 20 g) were immunized sub-
cutaneously with 20 μg of CML-KLH or CML-BSA antigen as in
Becker-Finco et al. [15]. Serum samples were diluted (1:100) and
submitted to an ELISA (detailed below).
Animals whose serum analysis led to A490 nm higher than
1.0 for CML-protein and low cross-reactivity to native carrier
protein (A490 nmo0.05) received an intravenous boost of 5 μg
CML-protein in 100 μL of PBS. Three days later, spleens from hy-
perimmunized mice were collected and their splenocytes were
fused to Sp2/0 myeloma cells for hybridoma generation [15,16].
Hybridoma supernatants were ELISA-screened using CML-
protein and native carrier protein. CML-protein positive hy-
bridomas were subsequently expanded and cloned. One cell line,
named mAb 2D6, which was positive for CML-BSA or CML-KLH but
negative for BSA or KLH was selected, submitted to additional
subclonings leading to clone 2D6G2. Anti-CML monoclonal anti-
bodies (mAbs) were tested using the ELISA described below. mAbs
were puriﬁed by a single-step immunoafﬁnity chromatography
using Protein A/G Sepharoses 4B fast ﬂow prepared according to
the manufacturer's instructions (Sigma-Aldrich).
Analysis of the cDNA encoding mAb 2D6G2 variable heavy (VH)
and light (VL) chain domains, sequence analysis, and database
search.
Total RNA was isolated from hybridoma 2D6G2. cDNAs encod-
ing the antibody variable domains (Immunoglobulin heavy chain
variable, IGHV; Immunoglobulin light chain variable, IGκV) were
cloned after RT-PCR using degenerate primers. IGH-For (GAC AGT
GGA TAR ACM GAT GG) and IGH-Rev (GAG GTS MAR CTG CAG SAG
TCWGG) for mAb 2D6G2 VH ampliﬁcation, and V-KAPPA For (GGA
TAC AGT TGG TGC AGC ATC) and V-KAPPA Rev (GAT ATT GTG CTA
ACT CAG TCT) for mAb 2D6G2 light chain variable VL ampliﬁca-
tion. PCR products were inserted into the cloning vector pGEM-T
(Promega A3610) before being sequenced and analyzed according
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To compare V-REGION sequences of immunoglobulins, Im-
MunoGenetTics (IMGT) unique numbering and standards, ap-
proved by the World Health Organization (WHO)/International
Union of Immunological Societies (IUIS) Nomenclature Sub-
committee for Immunoglobulins and T Cell Receptors was used.
The Web interface IMGT tools (IMGT/V-QUEST) and databases
(IMGT/LIGM-DB and IMDT/3D structure-DB) were also used [18].3. ELISA protocols
3.1. Direct format
CML-protein (100 mL, 10 mg/mL or an increasing concentration 0.3–
40 μg/mL) was immobilized onto 96-well plates (Immunonunc Ther-
mo Fisher Scientiﬁc, Rockford, IL) and incubated at 4 °C overnight.
Nonspeciﬁc binding sites were saturated with 120 μL of 2% casein for
60 min. The plate was then incubated with 100 μL of hybridoma
culture supernatant, monoclonal (1 μg/mL) or polyclonal (diluted
1:400) anti-AGE antibody for an additional 60 min at 37 °C.The plate
was incubated for an additional 60 min with HRP-conjugated anti-
mouse IgG. Finally, 20 μL of the substrate solution (1,2-phenylene-
diamine dihydrochloride, Sigma-Aldrich, St. Louis, MO) was added to
each well for 20 min. The reaction was stopped with 1.0 M sulfuric
acid, and the absorbance was measured at 490 nm on a microplate
ELISA reader (Bio-Rad 550, Japan).
3.2. Competitive format
96-well plates (Immunonunc, Thermo Fisher Scientiﬁc, Rock-
ford, IL) were coated overnight with a solution of CML-protein
(100 mL, 10 mg/mL) in carbonate buffer pH 9.6. After blocking (2%
casein in PBS) 100 ml of the human sera (CKD patients) diluted 1:10
in presence 0.1 μg/mL of mAb 2D6G2 and incubated for 120 min at
37 °C. Three washing with PBS (pH 7.4) containing 0.1% Tween 20
were performed between each of the intermediate steps. The plate
was incubated for an additional 60 min. with HRP-conjugated
anti-mouse IgG. Bound antibody was detected as described above.
For standard curves, plates were incubated with 0.1 mg/mL of mAb
2D6G2 (100 mL in the presence of CML-HSA at various concentra-
tions (0.4–200 ng/mL)).
3.3. Correlation analysis between CML-HSA concentration and other
biological parameters - statistical analysis
CKD patients were distributed between ﬁve stages, being stage
1 mild CKD, and 5 severe CKD. All the variants used in the stats
analysis (CML-HSA levels, CKD stages and GFR) had a nonpara-
metric distribution, for this reason we used rank correlation
coefﬁcient or Spearman’s rho (ρ), that is a test to nonparametric
measure of statistical dependence between two variables. It as-
sesses how well the relationship between two variables can be
described using a monotonic function. In this way, we performed
the correlation of CML levels (ng/dL) and GFR (MDRD)
mL/min/1.73 m2 with creatinin, albumin, phosphorous, calcium
and glucosis, wich resulted in the correlation represented by ρ and
signiﬁcance represented by P.
Statistical analyses were performed using JMP Windows ver-
sion 8.1 (SAS Institute Inc., Cary, N.C., USA). Data were analyzed by
one-way ANOVA for unpaired data. For multiple pair wise com-
parisons, a Bonferroni correction was performed to adjust the
signiﬁcance level. Correlations were performed by the Spearman
rank test (ρ). Results are expressed as mean7standard error of the
mean (SEM). A P valueo0.0001 was considered signiﬁcant.4. Results
The main clinical and biochemical characteristics of the patient
biological samples used in the antibody tests are summarized in
Supplemental Table 1. The median GFR was 37 mL/min (ranging
from 12 to 107 mL/min). Patients were distributed among CKD
stages 1–5 according to the National Kidney Foundation criteria.
4.1. Characterization of CML-proteins
Fig. 1A shows CML-protein synthesis. The difference in elec-
trophoretic mobility indicates glycation of the synthetized samples
(Fig. 1B). It was also possible to visualize the molecular mass al-
teration of HSA (native protein) and CML-protein (glycated pro-
tein) by mass spectrometry. The HSA spectrum displayed a peak of
66 kDa and the CML-HSA displayed a 70 kDa peak. The difference
in 4 kDa observed by spectroscopy, suggests an average formation
of 19 new CML domains per molecules while 59 potential sites of
conjugation (Lys residues) have been reported in the sequence of
HSA (Gene accession number AAA98797) (Fig. 1C). Following
coupling of HSA with glyoxilic acid, no change in solubility neither
any formation of aggregates was observed.
4.2. Generation of anti-CML antibody
4.2.1. Characterization of polyclonal antibodies
The serum of immunized mice was collected and tested in a
direct ELISA. Immunization with glycated protein CML-KLH in-
duced the production of polyclonal antibodies that were highly
reactive with CML-BSA but not with native BSA and the signal
observed was even higher than the one observed when testing
anti CML-BSA polyclonal antibodies against immobilized CML-
KLH. These observations are in favor of the production of anti-
bodies speciﬁc for the CML domain and directed the choice of an
immune serum that presented the lowest reactivity against the
native form of the carrier molecule and high reactivity against the
glycated protein. The serum from mice immunized with CML-KLH
was then used in the process of monoclonal antibody selection
and production (Fig. 2A).
4.3. Characterization of the mAbs
In a direct ELISA, the antibodies evaluated were capable to re-
cognize the CML domain, while no cross-reactivity was observed
with the native carrier proteins (Fig. 2B). The hybridoma 2D6 and
3G3 were selected and submitted to successive dilutions for sub-
cloning. Here again, fourteen subclones (8 derived from clone 2D6
and 6 derived from clone 3G3) were evaluated for the recognition
of CML-HSA and HSA native form in a direct ELISA. Each subclone
secreted antibodies capable of reacting with CML-HSA but not
with native HSA coated on microtitration wells (Fig. 2C). ELISA
analysis also demonstrated that all subclones derived from hy-
bridoma 2D6 exhibit a higher capacity to secrete speciﬁc anti-
bodies as compared to subclones derived from 3G3. Thus, subclone
2D6G2 was selected for puriﬁcation and characterization. ELISA
allowed us to show that antibody secreted by subclone 2D6G2 was
able to bind to the CML structural pattern not only in CML-HSA,
but also in CML-BSA and CML-KLH, in a dose-dependent manner
and this conﬁrmed the sharp antigen-binding speciﬁcity of 2D6G2
murine antibody (Fig. 2D).
4.4. Analysis of the cDNA encoding mAb 2D6G2 VH and VL domains
Before carrying any ﬁne functional immunoassays, the cDNA
encoding antibody 2D6G2 IGH-V and IGKappa-V domains were
ampliﬁed by PCR from two distinct preparations of RNA isolated
Fig. 1. Molecular characterization of the modiﬁed proteins. (A) Schematic drawing of CML-protein formation. (B) The synthesized samples were separated by SDS-PAGE after
Coomassie staining. MW, molecular weight marker. (C) Mass spectrometry HSA and CML-HSA by MALDI TOF MS.
Fig. 2. Reactivity of polyclonal and monoclonal antibodies by ELISA direct. (A) Reactivity of polyclonal antibodies produced against glycated proteins and cross-reactivity
against native protein. (B) Reactivity of cell supernatants against glycated and non-glycated proteins. (C) Speciﬁcity of monoclonal antibodies against CML-HSA and cross-
reactivity to HSA. (D) Dose dependence of mAb 2D6G2 against CML-proteins.
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products, VH and VL, presented bands around 350 bp after agarose
gel electrophoresis analysis (Fig. 3A). Sequencing and in silico
analysis indicated that 2D6G2 IGH-V and IGKappa-V sequenceswere unique. Complementary determining regions (CDRs) frame-
work were easily identiﬁed. No key conserved residues were
mutated in the framework regions, suggesting that the sequences
were correctly rearranged and functional. The VH gene belonged
Fig. 3. Cloning of mAb2D6G2 cDNA encoding antibody variable domains. (A) Agarose gel electrophoresis of cDNA encoding IGkV (lane Vk) and IGHV (lane VH) domains. M:
100-bp DNA ladder. (B) “Collier de perles” of mAb 2D6G2 antibody variable domains.
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identity with Mus musculus IGHV5-12-2*01, while the VL gene
belonged to the IGKV5 family with 94% identity withMus musculus
IGKappaV5-43*01 (Fig. 3B).
4.5. Characterization of mAb 2D6G2 with the sera of CKD patients
After optimization of several parameters (data not shown), a
competitive ELISA was settled (Fig. 4). Serum CML-HSA of patients
presented different percentages of inhibition (Fig. 5A). A standard
curve of the known concentrations of CML-HSA allowed the
quantiﬁcation of this compound in the CKD sera. The detection
limit of CML in this assay was 0.4 ng/dL, an amount equivalent to
5% inhibition (Fig. 5B). In this competitive ELISA, 20% inhibition
corresponded to 12 ng/dL CML-HSA, a concentration correspond-
ing to what is observed in patients with more advanced stages of
CKD.Fig. 4. Detection of synthesized CML-HSA by competitive ELISA using mAb 2D6G2. (A) A
as decreasing absorbance correlated with increasing competitor. (B) Principle of the assay
0.4-200 ng) was mixed with 0.1 μg/mL of mAb 2D6G2 anti-CML antibody. A portion of
conﬁrmed by adding anti-immunoglobulin.Using this competitive ELISA, it was possible to correlate CML-
HSA serum levels with CKD stages (Fig. 5C) according to Clinical
Practice Guidelines for Chronic Kidney Disease. Furthermore, in-
verse correlation was observed between serum CML-HSA and the
GFR (Fig. 5D).
Table 1 summarizes the correlations between CML-HSA con-
centrations and the biochemical parameters of the biological
samples analyzed here. CML-HSA concentration was directly re-
lated to CKD stage, as well as to creatinine, phosphor, and glucose.
In contrast, a negative correlation was found between serum CML-
HSA with GFR and calcium. All analyses indicated Po0.05.5. Discussion
AGEs synthesis is related to several diseases and their titration
in the serum of patients may be of the greatest interest forstandard curve of the known concentrations of CML-HSA. The results are expressed
. CML-HSA (10 μg/mL) was immobilized on plate. The sample to be tested (CML-HSA
the mixture (100 μL) was added to the plate prepared above. The reactions were
Fig. 5. Detection of CKD serum CML levels. (A) Analysis of the competition between the CML-HSA levels in human serum and the immobilized synthesized CML-HSA for
binding to mAb 2D6G2. The results are expressed as increasing inhibition correlated with increasing competitor. (B) A curve correlating inhibition and CML-HSA levels.
(C) Correlation between CKD stages and CML-HSA concentration. (D) Relationship between serum levels of CML-HSA and GFR. CKD stages were performed following KDOQI
Clinical Practice Guidelines for Chronic Kidney Disease.
Table 1
Correlations of CML-HSA levels with CKD stages and GFR, and biochemical characteristics of patients serum.
CML-HSA (ng/dL) GFR (MDRD) mL/min/1.73 m2
ρ P ρ P
CKD stages 0.95 o0.0001 0.98 o0.0001
GFR (MDRD) mL/min/1.73 m2 0.92 o0.0001 NS NS
Creatinine (mg/dL) 0.91 o0.0001 0.96 o0.0001
Albumin (g/dL) 0.36 NS 0.37 NS
Phosphor (mg/dL) 0.45 o0.02 0.46 o0.024
Calcium (md/dL) 0.79 o0.0001 0.62 o0.0012
Glucose 0.44 o0.033 0.33 NS
NS¼not signiﬁcant.
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immunoassays could be valuable approaches to reach this goal but
this strategy still suffers from the lack of reliable speciﬁc anti-
bodies with applications often limited to immunohistochemical
studies and usually no correlation is really observed between
serum immunotitration of AGEs and the CKD clinical stage [19–21].
This may be related to functional characteristics of the antibodies
developed so far, which are not suited for sensitive immunotitra-
tion [22,23].
Because CML concentration is increased in serum of patients
who have CKD and other diseases such as diabetes with compli-
cations including nephropathy, retinopathy, and atherosclerosis its
remains important to design sensitive immune titration assays and
select immunoprobes able to detect uremic toxins and correlate
with clinical aspects [24].
Even if hybridoma technology is conceptually simple, it depends
upon complex biological systems and obtaining speciﬁc and reliable
mAbs is never entirely predictable. This is particularly true when the
target is an hapten that is unable to initiate an immune response byitself. Here, CML was conjugated to various carriers to elicit and im-
mune response. KLH, BSA, and HSA were used in the presence of
glyoxylic acid and the oxidizing reagent NaCNBH3, which directed the
non-enzymatic glycation reaction in order to produce the CML do-
main. Although EDC, glutaraldehyde and BS3 are conventional cou-
pling reagents, their efﬁcacity remains discussed to produce viable
antibodies against CML [25]. Indeed, here the efﬁciency of direct gly-
cation was clearly demonstrated by SDS-PAGE and conﬁrmed by mass
spectrometry analysis, in which differences between the native car-
riers and CML-carrier conjugates molecular mass were observed. In
addition the ELISA screening for cross-reactivity allowed us to select
antibodies strictly speciﬁc for CML.
mAb 2D6G2 was identiﬁed and used as an immunological
probe to analyze sera from patients. The competitive ELISA de-
veloped here was sensitive with a linear range from 0.4 to 200 ng/
dL of CML and a detection limit of 0.4 ng/dL. In addition, the re-
sults collected correlated with the CKD proﬁle of patients who
suffer from an inadequate clearance of these molecules. All to-
gether these observations make the monoclonal antibody 2D6G2 a
A.B. Finco et al. / Biochemistry and Biophysics Reports 6 (2016) 142–148148valuable candidate to design diagnostic kits for the titration of
CML protein adducts in unknown samples even if standardization
will still be required.
Finally, several strategies could even be considered to further
improve the sensitivity of the assay. As a ﬁrst strategy, antibody
2D6G2 could be biotinylated to amplify the signal [26]. Even more
interesting, 2D6G2 could be produced as a recombinant colori-
metric tracer in which scFv 2D6G2 is genetically fused to a re-
porter with a well-deﬁned coupling ratio. This strategy favors the
design of homogeneous immunoconjugates and consequently in-
creases assay performances. Besides, additional mutagenesis re-
mains possible to alter the functional properties of both entities
leading to variants with increased colorimetric activity or modiﬁed
antigen selectivity. Recently, Alvarenga et al. [27] proposed to
apply recombinant antibody technologies to the production of a
bivalent colorimetric immune probe consisting in the V-domains
of an antibody fused to a colorimetric tracer such as alkaline
phosphatase. The same strategy can be used here because the
cDNAs encoding 2D6G2 V-domains have been cloned and se-
quenced. This precaution was taken to follow the recommenda-
tions of researchers who recently pointed out the need to stan-
dardize antibodies used in research in order to make reliable
binding reagents for all [28].6. Conclusion
In conclusion, 2D6G2 is a novel monoclonal antibody that al-
lows sensitive detection and titration of CML, the major antigenic
AGE structure. Further developments should enable the design of
diagnostic assays but also inhibitors of AGEs that could trigger
beneﬁcial effects in diabetic complications [9]. Finally, the avail-
ability of the sequence makes this antibody available to all re-
searchers for the development of standardized binding reagents
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